Xalkori 250mg

The remedy Xalkori 250 mg is made on the basis of the substance Crizotinib, which is a representative of a group of antitumor remedies that inhibit tyrosine kinase receptors. This remedy is used in certain oncopathologies, strictly according to the doctor’s prescription, who has experience in conducting antitumor therapy.

Application

Xalkori 250 mg is prescribed for lung cancer (non-small cell, common), expressing anaplastic lymphoma kinase. The appointment takes into account:
Stage of the disease;
Individual features (age, sex);
The presence of other diseases in acute or chronic form.

It is very important that the patient inform the doctor about all the diseases and taking other medications on an ongoing basis before the appointment of ” Xalkori “, as there are certain contraindications, with some Crizotinib remedies is not compatible.

Protocol of using

The standard dosage of Xalkori is 250 mg, taken once a day, regardless of food intake. Depending on the patient’s response to this medication, the attending physician can adjust the dose. Treatment with Crizotinib is long and does not stop until a positive result of this therapy is noted. This approach is due to the fact that the drug has a cumulative effect, accumulating in the body and increasing its effect. Important is the preliminary study of the lung tumor on its ability to express the enzyme ALK – treatment with Crizotinib will only be effective if the result is positive. This remedy is not used during pregnancy or when breastfeeding.

The effectiveness of the using of Xalkori 250 mg (Crizotinib)

Crizotinib is the only remedy that has demonstrated a higher survival rate of patients without progression of the tumor process compared to traditional chemotherapy with platinum-containing substances. The effectiveness of the treatment of ALK-positive advanced NSCLC with the help of Xalkori 250 mg was confirmed in two large international studies. Today this remedy has been approved for use in 74 countries.

Xalkori 250 mg is a modern medicinal product used in oncology for the therapy of certain malignant neoplasms. The mechanism of action of Xalkori is associated with the blocking of specific receptors that participate in the division of tumor cells. As a result of taking the drug, natural processes of cell destruction increase, which leads to a decrease in the primary focus and metastatic tumors.

Xalkori 250 mg is a highly effective drug. Clinical studies have shown that the therapy with this drug reduces the size of the tumor, prevents metastasis, improves the well-being of patients and prolongs their life.

Contraindications

Xalkori 250 mg is not prescribed for the treatment of children, adolescents under the age of 18, pregnant and lactating women, patients with intolerance to any component of the drug, severe impairment of the liver and kidneys. To prevent adverse reactions of drug interaction, the patient should inform the physician of all medications taken.